Investor Relations

Corporate profile

Enlivex is a clinical stage biopharmaceutical company developing Allocetra™, a universal, off-the-shelf cell therapy platform designed to restore the homeostatic state of macrophages, for the treatment of inflammatory diseases.

Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life-debilitating conditions.

Investment Highlights

Strong IP strategy for novel therapeutic modality.

Favorable safety profile demonstrated across several clinical studies.

Proposed MOA supported by clinical data.

Optimized manufacturing process yielding ready-to-use doses of off-the-shelf cell therapy platform.

Multi-billion-dollar market opportunity in several inflammatory disease markets with high unmet need.

Seasoned management team with a track record of successfully advancing therapies through regulatory approval.

Recent news releases

View all
11

September

2025

Allocetra™ demonstrated statistically significant and clinically meaningful improvements in pain and function in Phase IIa trial in primary osteoarthritis patients Six-month data expected November 2025; Phase IIb trial initiation planned for Q2 2026 Nes-Ziona, Israel, Sept. 11, 2025...
9

September

2025

Nes-Ziona, Israel, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of an Israeli patent, numbered 290470, titled, "THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF...
18

August

2025

ENX-CL-05-001 Trial: 3-months topline data - In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee pain and 26% improvement in knee function, were observed in the AllocetraTM treatment arm vs placebo...